JPH11508914A5 - - Google Patents

Info

Publication number
JPH11508914A5
JPH11508914A5 JP1997505748A JP50574897A JPH11508914A5 JP H11508914 A5 JPH11508914 A5 JP H11508914A5 JP 1997505748 A JP1997505748 A JP 1997505748A JP 50574897 A JP50574897 A JP 50574897A JP H11508914 A5 JPH11508914 A5 JP H11508914A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997505748A
Other languages
English (en)
Japanese (ja)
Other versions
JP4084415B2 (ja
JPH11508914A (ja
Filing date
Publication date
Priority claimed from GBGB9514074.5A external-priority patent/GB9514074D0/en
Priority claimed from GBGB9520311.3A external-priority patent/GB9520311D0/en
Priority claimed from GBGB9522837.5A external-priority patent/GB9522837D0/en
Application filed filed Critical
Priority claimed from PCT/SE1996/000911 external-priority patent/WO1997003084A1/en
Publication of JPH11508914A publication Critical patent/JPH11508914A/ja
Publication of JPH11508914A5 publication Critical patent/JPH11508914A5/ja
Application granted granted Critical
Publication of JP4084415B2 publication Critical patent/JP4084415B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50574897A 1995-07-11 1996-07-04 新しい血小板凝集抑制剤 Expired - Fee Related JP4084415B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9514074.5A GB9514074D0 (en) 1995-07-11 1995-07-11 Compounds
GB9514074.5 1995-07-11
GBGB9520311.3A GB9520311D0 (en) 1995-10-05 1995-10-05 Compounds
GB9520311.3 1995-10-05
GBGB9522837.5A GB9522837D0 (en) 1995-11-08 1995-11-08 Compounds
GB9522837.5 1995-11-08
PCT/SE1996/000911 WO1997003084A1 (en) 1995-07-11 1996-07-04 New inhibitors of platelet aggregation

Publications (3)

Publication Number Publication Date
JPH11508914A JPH11508914A (ja) 1999-08-03
JPH11508914A5 true JPH11508914A5 (cg-RX-API-DMAC7.html) 2004-08-05
JP4084415B2 JP4084415B2 (ja) 2008-04-30

Family

ID=27267806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50574897A Expired - Fee Related JP4084415B2 (ja) 1995-07-11 1996-07-04 新しい血小板凝集抑制剤

Country Status (25)

Country Link
US (1) US5747496A (cg-RX-API-DMAC7.html)
EP (1) EP0840740B1 (cg-RX-API-DMAC7.html)
JP (1) JP4084415B2 (cg-RX-API-DMAC7.html)
KR (1) KR100444123B1 (cg-RX-API-DMAC7.html)
CN (1) CN1069321C (cg-RX-API-DMAC7.html)
AR (1) AR003453A1 (cg-RX-API-DMAC7.html)
AT (1) ATE217010T1 (cg-RX-API-DMAC7.html)
AU (1) AU699034B2 (cg-RX-API-DMAC7.html)
BR (1) BR9609467A (cg-RX-API-DMAC7.html)
CA (1) CA2226758A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ297200B6 (cg-RX-API-DMAC7.html)
DE (1) DE69621021T2 (cg-RX-API-DMAC7.html)
EE (1) EE03616B1 (cg-RX-API-DMAC7.html)
HU (1) HU221880B1 (cg-RX-API-DMAC7.html)
IL (1) IL122814A (cg-RX-API-DMAC7.html)
IS (1) IS1790B (cg-RX-API-DMAC7.html)
MY (1) MY116542A (cg-RX-API-DMAC7.html)
NO (1) NO310624B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ312258A (cg-RX-API-DMAC7.html)
PL (1) PL182680B1 (cg-RX-API-DMAC7.html)
SA (1) SA96170272B1 (cg-RX-API-DMAC7.html)
SK (1) SK283206B6 (cg-RX-API-DMAC7.html)
TR (1) TR199800019T1 (cg-RX-API-DMAC7.html)
TW (1) TW427996B (cg-RX-API-DMAC7.html)
WO (1) WO1997003084A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4125790B2 (ja) * 1996-12-20 2008-07-30 アストラゼネカ・アクチエボラーグ トリアゾロ[4,5−d]ピリミジニル誘導体および医薬としてのその使用
TW530058B (en) * 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702772D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702774D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
CN1291193A (zh) * 1998-02-17 2001-04-11 阿斯特拉曾尼卡英国有限公司 新的三唑并(4,5-d)嘧啶化合物
SE9802574D0 (sv) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US20020169730A1 (en) * 2001-08-29 2002-11-14 Emmanuel Lazaridis Methods for classifying objects and identifying latent classes
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US7674791B2 (en) * 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
EP1618108A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
US7834014B2 (en) * 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092170A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
DE602004027409D1 (de) * 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7749980B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7932376B2 (en) * 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
EP2081433A2 (en) * 2006-10-31 2009-07-29 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
WO2010022126A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2011216991A1 (en) 2010-02-16 2012-08-30 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
BR112014013085A2 (pt) 2011-11-30 2017-06-13 Actavis Group Ptc Ehf forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
WO2014206188A1 (zh) * 2013-06-27 2014-12-31 苏州明锐医药科技有限公司 替格瑞洛的制备方法
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑(2‑(甲硫基)乙基)‑2‑((3,3,3‑三氟丙基)硫代)‑9h‑嘌呤及其制备方法和应用
CN112915063B (zh) * 2021-01-25 2022-12-20 刘红枚 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
RU2770405C1 (ru) * 2021-07-05 2022-04-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные триазола, проявляющие антиагрегационную активность

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
JP2619710B2 (ja) * 1989-02-27 1997-06-11 日本製紙 株式会社 2′,3′−ジデオキシプリンヌクレオシド類の製造方法
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH08506343A (ja) * 1993-02-03 1996-07-09 ジェンシア・インコーポレイテッド リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質

Similar Documents

Publication Publication Date Title
JP2000500445A5 (cg-RX-API-DMAC7.html)
JP2000500033A5 (cg-RX-API-DMAC7.html)
JP2000500228A5 (cg-RX-API-DMAC7.html)
JP2000500440A5 (cg-RX-API-DMAC7.html)
JP2000500327A5 (cg-RX-API-DMAC7.html)
JP2000500145A5 (cg-RX-API-DMAC7.html)
JP2000500155A5 (cg-RX-API-DMAC7.html)
JP2000500406A5 (cg-RX-API-DMAC7.html)
JP2000500361A5 (cg-RX-API-DMAC7.html)
JP2000500115A5 (cg-RX-API-DMAC7.html)
JP2000500322A5 (cg-RX-API-DMAC7.html)
JP2000500258A5 (cg-RX-API-DMAC7.html)
JP2000500342A5 (cg-RX-API-DMAC7.html)
JP2000500192A5 (cg-RX-API-DMAC7.html)
JP2000500112A5 (cg-RX-API-DMAC7.html)
JP2000500226A5 (cg-RX-API-DMAC7.html)
JP2000500051A5 (cg-RX-API-DMAC7.html)
JP2000500397A5 (cg-RX-API-DMAC7.html)
JP2000500407A5 (cg-RX-API-DMAC7.html)
JP2000500019A5 (cg-RX-API-DMAC7.html)
JP2000500166A5 (cg-RX-API-DMAC7.html)
JP2000500125A5 (cg-RX-API-DMAC7.html)
JP2000500044A5 (cg-RX-API-DMAC7.html)
JP2000500346A5 (cg-RX-API-DMAC7.html)
JP2000500257A5 (cg-RX-API-DMAC7.html)